This guideline provides a comprehensive clinical care pathway for patients with COVID-19, from screening and identification through treatment, monitoring, and discharge from care.

Special consideration is given to vulnerable populations including:

• Pediatric patients

• Older adults

• Pregnant women

• Immunocompromised individuals

• Patients with chronic comorbidities

The guideline emphasizes a coordinated multidisciplinary approach involving clinicians, nurses, laboratory personnel, physiotherapists, mental-health professionals, and public-health teams.

COVID-19 Care Pathway Concept

After entry into a health facility:

1. Patient is screened

2. Classified as suspect / probable / confirmed case

3. Enters COVID-19 care pathway

4. Receives continuous monitoring and treatment

5. Exits pathway after recovery, transfer, or death certification

Patients not meeting criteria follow the non-COVID clinical pathway.

Primary Objectives

• Deliver safe and quality clinical care

• Prevent onward viral transmission

• Reduce complications and mortality

• Provide psychosocial support

Psychosocial Support

Basic psychosocial interventions must be provided to:

• Patients diagnosed with COVID-19

• Family members

• Caregivers

• Bereaved relatives

• Recovered patients

Key Components

• Clear communication and reassurance

• Anxiety and fear reduction

• Grief counseling

• Address stigma and isolation stress

• Post-recovery reintegration support

Evidence-Based Practice Considerations

COVID-19 treatment evolves continuously due to emerging research. Multiple clinical trials evaluate antivirals, immunomodulators, and supportive therapies.

Therefore, guidance should be:

• Updated regularly

• Evidence-graded

• Holistic across the disease continuum

1.a DISEASE PATHOPHYSIOLOGY AND TIME COURSE

COVID-19 follows a dynamic multi-phase illness involving viral replication, immune activation, pulmonary injury, and systemic inflammatory response.

PHASE I — Asymptomatic Viral Replication Phase

Timeframe: Day 0 – Day 5

Pathophysiology

• Virus enters via respiratory mucosa

• Binds ACE2 receptors in nasal epithelium

• Rapid viral replication in upper airway

• Minimal immune response

• High infectivity despite absence of symptoms

Clinical Features

• No symptoms OR very mild symptoms

• Patient highly contagious

Clinical Importance

This phase drives community transmission.

Key Biological Events

• Nasopharyngeal viral load peaks

• Innate immunity activation begins

• No tissue damage yet

PHASE II — Symptomatic (Upper Respiratory / Systemic) Phase

Timeframe: Day 5 – Day 11

Pathophysiology

• Viral spread to conducting airways

• Activation of innate immune response

• Release of interferons and cytokines

• Mild epithelial inflammation

Common Symptoms

• Fever (often low-grade or absent)

• Chills

• Malaise

• Loss of smell (anosmia)

• Loss of taste (ageusia)

• Sore throat

• Myalgia

• Back pain

• Headache

• Cough

• Diarrhea

• Vomiting

Clinical Interpretation

Symptoms mainly immune-mediated rather than tissue destruction.

Risk Indicators of Progression

• Persistent fever >5 days

• Rising inflammatory markers

• Elderly or comorbid patients

PHASE III — Early Pulmonary Phase

Timeframe: Day 11 – Day 14

Pathophysiology

• Viral invasion of alveolar pneumocytes

• Localized lung inflammation

• Interstitial edema

• Impaired oxygen diffusion

Clinical Manifestations

• Shortness of breath

• Tachypnea

• Reduced exercise tolerance

• Mild hypoxia

Radiological Findings

• Peripheral ground-glass opacities

• Bilateral infiltrates

Clinical Significance

Transition point: mild disease → severe disease

Patients may rapidly deteriorate within 24–48 hours.

PHASE IV — Pulmonary and Hyperinflammatory Phase

Timeframe: Day 14 – Day 28

Pathophysiology

• Exaggerated immune response (cytokine storm)

• Diffuse alveolar damage

• Capillary leak

• Microvascular thrombosis

• Multi-organ injury

Often progresses to Acute Respiratory Distress Syndrome.

Clinical Features

• Progressive hypoxia

• Severe dyspnea

• Cyanosis

• Respiratory failure

• Shock

• Organ dysfunction

Possible Complications

• ARDS

• Sepsis

• Septic shock

• Thromboembolism

• Cardiac injury

• Kidney failure

Summary of Disease Timeline

Key Clinical Insight

Early antiviral and supportive management is most effective in Phase I–II, while anti-inflammatory and organ support strategies become critical in Phase III–IV.